Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:EOLS

Evolus Q2 2026 Earnings Report

Evolus logo
$5.98 -0.01 (-0.17%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$5.90 -0.08 (-1.34%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Evolus EPS Results

Actual EPS
N/A
Consensus EPS
-$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

Evolus Revenue Results

Actual Revenue
N/A
Expected Revenue
$81.55 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evolus Announcement Details

Quarter
Q2 2026
Date
8/4/2026
Time
After Market Closes
Conference Call Date
Wednesday, August 5, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Evolus Earnings Headlines

Evolus to Report Second Quarter Financial Results on August 5, 2026
July 22 at 9:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260722579511/en/Evolus-to-Report-Second-Quarter-Financial-Results-on-August-5-2026/
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260710949919/en/evolus-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
July 25 at 1:00 AM  |  Base Camp Trading (Ad)
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
July 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260708437892/en/evolus-announces-partnership-with-ibsa-to-develop-and-commercialize-market-leading-profhilo%c2%ae-in-the-united-states-expanding-its-injectable-portfolio-into-skin-quality/
Evolus (EOLS) Receives a Buy from Mizuho Securities
June 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/EOLS/pressreleases/2387554/evolus-eols-receives-a-buy-from-mizuho-securities/
Evolus to Participate in The Jefferies Global Healthcare Conference
May 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260519075871/en/evolus-to-participate-in-the-jefferies-global-healthcare-conference/
See More Evolus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evolus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evolus and other key companies, straight to your email.

About Evolus

Evolus (NASDAQ:EOLS) is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S. Food and Drug Administration in early 2019 for the temporary improvement in the appearance of moderate to severe frown lines. Jeuveau is marketed in the United States through a direct-sales model, supported by a dedicated sales force and a digital ordering platform. Evolus has also secured rights to commercialize Jeuveau in Canada and holds distribution agreements aimed at expanding its reach into select European markets.

Since launch, Evolus has invested in physician education and patient-focused support programs, collaborating with dermatologists, plastic surgeons and aesthetic specialists to build awareness of Jeuveau’s clinical profile. The company maintains a manufacturing partnership with a South Korean contract manufacturer, ensuring consistency in product quality and supply chain reliability. Evolus regularly publishes safety and efficacy data from post-marketing studies to reinforce confidence among healthcare providers and patients.

Under the leadership of President and Chief Executive Officer Megan Kilcoyne, who joined Evolus in 2019 and was appointed CEO in 2020, the company has expanded its commercial infrastructure and launched new initiatives in digital engagement. Evolus continues to pursue strategic partnerships and potential development candidates that align with its mission to deliver innovative, high-quality aesthetic solutions to markets worldwide.

View Evolus Profile
Earnings Tools